Skin cancer is one of the most common and biologically complicated cancers in the world, with both melanoma and nonmelanoma subtypes. According to recent research, epigenetic changes—including DNA methylation, histone modifications, chromatin remodeling, and non-coding RNA regulation—are crucial for the development, spread, metastasis, and resistance to treatment of tumors. Histone alterations alter chromatin states to favor tumorigenicity, dysregulated microRNAs further alter gene expression networks, and aberrant methylation patterns silence tumor suppressor genes while activating oncogenes. These reversible and dynamic changes not only promote carcinogenesis but also enhance malignant behavior by interacting with signaling pathways, such as PI3K/Akt/mTOR and MAPK. Comprehending these procedures yields vital information on prognostic markers, biomarkers for early detection, and innovative treatment approaches. The use of immunotherapies, phytochemical-based modulators, and epigenetic inhibitors is showing promise as a precision therapeutic strategy. This study examines the possibility of epigenome-targeted therapeutics in the fight against skin cancers in the future, as well as the mechanistic significance of epigenetics in the advancement of skin cancer and its interaction with oncogenic pathways.